Nephros Overview
Valuation check: NEPH's ROE is 14.51%, below the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow14.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Nephros (NEPH) currently reports a ROE of 14.51%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Nephros's ROE history and peer comparisons.
Nephros's ROE of 14.51% is lower than the Healthcare sector average of 20.77%. That is roughly 30.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Nephros's current 14.51% should be judged against Healthcare norms (sector average: 20.77%) and against NEPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 14.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Nephros, and consider following NEPH for alerts when major investors trade the stock.
Nephros is classified in the Healthcare sector. On ROE, it currently shows 14.51% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NEPH with unrelated industries.
